Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 January Pharma News Adding eltrombopag to immunosuppressive therapy improves response in severe aplastic anaemia Read more
2022 January Science Lentiviral globin therapy after reduced-intensity conditioning in adults with β-Thalassemias Read more
2022 January Clinical trials Betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia Read more
2022 January Clinical trials Axicabtagene ciloleucel as second-line treatment for relapsed/refractory large B-cell lymphoma Read more
Top
